Two Sigma Advisers LP Acquires 8,300 Shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC)

Two Sigma Advisers LP lifted its holdings in shares of ORIC Pharmaceuticals, Inc. (NASDAQ:ORIC) by 14.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 66,500 shares of the company’s stock after purchasing an additional 8,300 shares during the period. Two Sigma Advisers LP owned about 0.09% of ORIC Pharmaceuticals worth $537,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ORIC. Boxer Capital Management LLC bought a new stake in shares of ORIC Pharmaceuticals during the 4th quarter worth $13,982,000. Schonfeld Strategic Advisors LLC bought a new stake in ORIC Pharmaceuticals in the 4th quarter valued at about $5,845,000. Balyasny Asset Management L.P. raised its stake in ORIC Pharmaceuticals by 37.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,555,260 shares of the company’s stock valued at $12,551,000 after acquiring an additional 424,194 shares during the period. Diadema Partners LP bought a new stake in ORIC Pharmaceuticals in the 4th quarter valued at about $1,729,000. Finally, Price T Rowe Associates Inc. MD raised its stake in ORIC Pharmaceuticals by 16.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,295,025 shares of the company’s stock valued at $10,452,000 after acquiring an additional 180,140 shares during the period. 95.05% of the stock is currently owned by institutional investors.

ORIC Pharmaceuticals Trading Down 0.8%

Shares of NASDAQ ORIC opened at $8.40 on Wednesday. ORIC Pharmaceuticals, Inc. has a 12 month low of $3.90 and a 12 month high of $14.67. The firm has a market capitalization of $597.14 million, a price-to-earnings ratio of -4.62 and a beta of 1.37. The business has a 50-day moving average of $5.47 and a 200-day moving average of $7.68.

ORIC Pharmaceuticals (NASDAQ:ORIC) last issued its quarterly earnings data on Monday, May 5th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09. On average, analysts predict that ORIC Pharmaceuticals, Inc. will post -2.17 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ORIC. HC Wainwright reiterated a “buy” rating and set a $21.00 price target on shares of ORIC Pharmaceuticals in a research report on Monday, May 5th. JPMorgan Chase & Co. upped their price target on ORIC Pharmaceuticals from $21.00 to $22.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Guggenheim reiterated a “buy” rating on shares of ORIC Pharmaceuticals in a research report on Wednesday, February 26th. Oppenheimer decreased their price target on ORIC Pharmaceuticals from $15.00 to $12.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 6th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of ORIC Pharmaceuticals in a research report on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $19.17.

ORIC Pharmaceuticals Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.